{"id":"W3130576199","doi":"10.1158/1538-7445.sabcs20-gs3-01","title":"Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Taxane; Carboplatin; Pembrolizumab; Chemotherapy; Internal medicine; Oncology; Interim analysis; Clinical endpoint; Chemotherapy regimen; Paclitaxel; Premedication; Progression-free survival; Triple-negative breast cancer; Metastatic breast cancer; Phases of clinical research; Clinical trial; Breast cancer; Cancer; Surgery; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004027831,0.002280093,0.001827188,0.000659186,0.0003758178,0.001066599,0.001246646,0.001442977,0.008276328],"category_scores_gemma":[0.001722079,0.000458451,0.003644226,0.0006888808,0.000837621,0.0009103154,0.0007168186,0.00413658,0.0008957766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001406981,"about_ca_system_score_gemma":0.002046431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009241729,"about_ca_topic_score_gemma":0.002531609,"domain_scores_codex":[0.9987676,0.0007478742,0.00008350125,0.0001458351,0.0001160341,0.0001391321],"domain_scores_gemma":[0.9986134,0.0003314526,0.0004971736,0.0001114793,0.00009893613,0.0003476107],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9493271,0.008643201,0.003522503,0.001195547,0.004161254,0.00007217739,0.00006232027,0.001925331,0.009232766,0.0001962095,0.002992498,0.01866917],"study_design_scores_gemma":[0.7242401,0.2432681,0.01854248,0.00009762458,0.004812811,0.0001684266,0.00005285112,0.001308628,0.003908394,0.0005183213,0.003035209,0.00004692332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9721239,0.004026688,0.001140292,0.0009721493,0.0002290998,0.005190166,0.01169952,0.0002114892,0.004406675],"genre_scores_gemma":[0.9813669,0.001182122,0.001592786,0.001247255,0.0002305041,0.003940305,0.008070921,0.00003507437,0.002334136],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008276328,"threshold_uncertainty_score":0.02768701,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1062660827478111,"score_gpt":0.4343006938422686,"score_spread":0.3280346110944575,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}